P38 MAP kinase inhibitors as potential therapeutics for the treatment of joint degeneration and pain associated with osteoarthritis

Journal of Inflammation

Volumn 5, Issue , 2008, Pages

  Brown, Kimberly K ^a   Heitmeyer, Sandra A ^a   Hookfin, Erin B ^a   Hsieh, Lily ^a   Buchalova, Maria ^a   Taiwo, Yetunde O ^a   Janusz, Michael J ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 5 (2,6 DICHLOROPHENYL) 2 (2,4 DIFLUOROPHENYLTHIO)PYRIMIDO[1,6 B]PYRIDAZIN 6 ONE; CARRAGEENAN; INTERLEUKIN 1BETA; IODOACETIC ACID; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RAT; HYPERALGESIA; IC 50; JOINT DEGENERATION; MALE; NONHUMAN; OSTEOARTHRITIS; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; RAT;

ANIMALIA; RATTUS;

EID: 58149237274     PISSN: None     EISSN: 14769255     Source Type: Journal    
DOI: 10.1186/1476-9255-5-22     Document Type: Article

References (45)

1. Signaling transduction: target in osteoarthritis. F Berenbaum, Curr Opin Rheumatol 2004 16 616 622 10.1097/01.bor.0000133663.37352.4a 15314504
2. Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. JP Pelletier J Martel-Pelletier SB Abramson, Arthritis Rheum 2001 44 1237 1247 10.1002/1529-0131(200106)44: 6〈1237::AID-ART214〉3.0.CO;2-F 11407681
3. Biologics in development for rheumatoid arthritis: Relevance to osteoarthritis. SB Abramson Y Yazici, Adv Drug Deliv Rev 2006 58 2 212 225 10.1016/j.addr.2006.01.008 16567019
4. Cytokines as therapeutic targets for osteoarthritis. CJ Malemud, BioDrugs 2004 18 23 35 10.2165/00063030-200418010-00003 14733605
5. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. MD Tortorella AM Malfait E Arner, Osteoarthritis Cartilage 2001 9 539 552 10.1053/joca.2001.0427 11520168
6. Interleukin-1β-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. TA Samad KA Moore A Sapirstein S Billet A Allchorne S Poole JV Bonventre CJ Woolf, Nature 2001 410 471 475 10.1038/35068566 11260714
7. Endoneurial injection of TNF-alpha produces neuropathic pain behaviors. R Wagner RR Myers, NeuroReport 1996 7 2897 2901 10.1097/00001756-199611250-00018 9116205
8. Etanercept reduces hyperalgesia in experimental painful neuropathy. C Sommer M Schafers M Marziniak KV Toyka, J Peripher Nerv Syst 2001 6 67 72 10.1046/j.1529-8027.2001.01010.x 11446385
9. Tumor necrosis factor-α induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. M Schafers CI Svensson C Sommer LS Sorkin, J Neurosci 2003 23 2517 2521 12684435
10. Inhibition of p38 mitogen-activated protein kinase attenuates interleukin-1β-induced thermal hyperalgesia and inducible nitric oxide synthase expression in the spinal cord. CS Sung ZH Wen WK Chang KH Chan ST Ho SK Tsai YC Chang CS Wong, J Neurochem 2005 94 742 752 10.1111/j.1471-4159.2005. 03226.x 16033422
11. Infliximab and methotrexate in the treatment of rheumatoid arthritis. PE Lipsky D van der Heijde EW St Claire DE Furst FC Breedveld JR Kalden JS Smolen M Weisman P Emery M Feldmann GR Harriman RN Maini, N Engl J Med 2000 343 1594 1602 10.1056/NEJM200011303432202 11096166
12. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor α for crohn's disease. SR Targan SB Hanauer SJH van Deventer L Mayer DH Present T Braakman KL DeWoody TF Schaible PJ Rutgeerts, N Engl J Med 2008 337 1029 1034 10.1056/NEJM199710093371502
13. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. SB Hanauer BG Feagan GR Lichtenstein LF Mayer S Schreiber JF Colombel D Rachmilewitz DC Wolf A Olson W Bao P Rutgeerts, The Lancet 2002 359 1541 1549 10.1016/S0140-6736(02)08512-4
14. Adalimumab, a fully human anti-tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. ME Weinblatt EC Keystone DE Furst LW Moreland MH Weisman CA Birbara LA Teoh SA Fischkoff EK Chartash, Arthritis Rheum 2003 48 35 45 10.1002/art.10697 12528101
15. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. ME Weinblatt JM Kremer AD Bankhurst KJ Bulpitt RM Fleischmann RI Fox CG Jackson M Lange DJ Burge, N Engl J Med 1999 340 253 259 10.1056/NEJM199901283400401 9920948
16. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate. S Cohen E Hurd J Cush M Schiff ME Weinblatt LW Moreland J Kremer MB Bear WJ Rich D McCabe, Arthritis Rheum 2002 46 614 624 10.1002/art.10141 11920396
17. The p38 MAP kinase pathway as a therapeutic target in inflammatory disease. J Saklatvala, Curr Opin Pharmacol 2004 4 372 377 10.1016/j.coph.2004. 03.009 15251131
18. The many paths to p38 mitogen-activated protein kinase activation in the immune system. JD Ashwell, Nature Reviews 2006 6 532 540 10.1038/nri1865 16799472
19. Novel homologues of CSBP/p38 MAP kinase. S Kumar PC McDonnell RJ Gum AT Hand JC Lee, Biochem Biophys Res Comm 1997 235 533 538 10.1006/bbrc.1997.6849 9207191
20. RWJ 6 a potent, orally active inhibitor of p38 mitogen activated protein kinase. SA Wadsworth DE Cavender SA Beers P Lalan PH Schaffer EA Malloy W Wu B Fahmy GC Olini JE Davis JL Pellegrino-Gensey MP Wachter JJ Siekierha, J Pharmacol Exp Ther 7657 291 680 687
21. Specificity and mechanism of action of some commonly used protein kinases inhibitors. SP Davies H Reddy M Caivano P Cohen, Biochem J 2000 351 95 105 10998351 10.1042/0264-6021:3510095
22. VX-745, a selective p38 inhibitor. F Salituro, American Chemical Society 33rd Middle Atlantic Regional Meeting Newark, DE May 15-17 2000 IDDB3 meeting report by Decicco C
23. A small molecule-kinase interaction map for clinical kinase inhibitors. MA Fabian WH Biggs DK Treiber CE Atteridge MD Azimioara MG Benedetti TA Carter PT Ciceri PT Edeen M Floyd JM Ford M Galvin JL Gerlach RM Grotzfeld S Herrgard DE Insko MA Insko AG Lai JM Lelias SA Mehta ZV Milanov AM Velasco LM Wodicka HK Patel PP Zarrinkar DJ Lockhart, Nat Biotechnol 2005 23 329 336 10.1038/nbt1068 15711537
24. A quantitative analysis of kinase inhibitor selectivity. MW Karaman S Herrgard DK Treiber P Gallant CE Atteridge BT Campbell KW Chan P Ciceri MI Davis PT Edeen R Faraoni M Floyd JP Hunt DJ Lockhart ZV Milanov MJ Morrison G Pallares HK Patel S Pritchard LM Wodicka PP Zarrinkar, Nat Biotechnol 2008 26 127 132 10.1038/nbt1358 18183025
25. Pharmacological profile of SB 20 a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. AM Badger JN Bradbeer B Votta JC Lee JL Adams DE Griswold, J Pharmacol Exp Ther 3580 279 1453 1461
26. Disease-modifying activity of SB 24 a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant arthritis. AM Badger DE Griswold R Kapadia S Blake BA Swift SJ Hoffman GB Stroup E Webb DJ Rieman M Gowen JC Boehm JL Adams JC Lee, Arthritis Rheum 2235 43 175 183 10.1002/1529-0131(200001)43:1〈175::AID-ANR22〉3.0.CO;2-S
27. In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. JP Pelletier JC Fernandes J Brunet F Moldovan D Schrier C Flory J Martel-Pelletier, Arthritis Rheum 2003 48 1582 1593 10.1002/art.11014 12794826
28. Moderation of iodoacetate-induced experimental osteoarthritis in rats by matrix metalloproteinase inhibitors. MJ Janusz EB Hookfin SA Heitmeyer JF Woessner AJ Freemont JA Hoyland KK Brown LC Hsieh NG Almstead B De MG Natchus S Pikul YO Taiwo, Osteoarthritis Cartilage 2001 9 751 760 10.1053/joca.2001.0472 11795995
29. A new sensitive method for measuring thermal nociception in cutaneous hyperalgesia. K Hargreaves R Dubner F Brown C Flores J Joris, Pain 1988 32 77 88 10.1016/0304-3959(88)90026-7 3340425
30. Osteoarthritis and cartilage: The role for cytokines. MB Goldring, Curr Rheumatol Rep 2000 2 469 475 10.1007/s11926-000-0021-y
31. Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. JJ Nietfeld B Wilbrink M Helle JL van Roy W den Otter AJ Swaak O Huber-Bruning, Arthritis Rheum 1990 33 1695 1701 10.1002/art.1780331113 2242066
32. Selective activation of the mitogen-activated protein kinase subgroups c-Jun NH2 terminal kinase and p38 by IL-1 and TNF in human articular chondrocytes. Y Geng Valbracht M Lotz, J Clin Invest 1996 98 2425 2430 8941662 10.1172/JCI119056
33. In vitro effects of diacerhein and rhein on interleukin 1 and tumor necrosis factor-α systems in human osteoarthritic synovium and chondrocytes. J Martel-Pelletier F Mineau FC Jolicoeur JM Cloutier JP Pelletier, J Rheumatol 1998 25 753 762 9558181
34. Diacerhein and rhein reduce the ICE-induced IL-1β and IL-18 activation in human osteoarthritic cartilage. F Moldovan JP Pelletier FC Jolicoeur JM Cloutier J Martel-Pelletier, Osteoarthritis Cartilage 2000 8 186 196 10.1053/joca.1999.0289 10806046
35. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebo controlled trial. JP Pellitier M Yaron B Haraoui P Cohen MA Nahir D Choquette I Wigler IA Rosner AD Beaulieu the Diacerein Study Group, Arthritis Rheum 2000 43 2339 2348 10.1002/1529-0131(200010)43:10〈2339::AID- ANR23〉3.0.CO;2-P 11037895
36. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee. K Pavelka T Trc K Karpas P Vitek M Sedlackova V Vlasakova J Bohmova J Rovensky, Arthritis Rheum 2007 56 4055 4064 10.1002/art.23056 18050202
37. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a three-year, placebo controlled trial. M Dougados M Nguyen L Berdah B Mazieres E Vignon M Lequesne for the ECHODIAH Investigators Study group, Arthritis Rheum 2001 44 2539 2547 10.1002/1529-0131(200111)44: 11〈2539::AID-ART434〉3.0.CO;2-T 11710710
38. Efficacy of etanercept in the treatment of acute, severe sciatica: a pilot study. S Genevay S Stringelin C Gabay, Ann Rheum Dis 2004 63 1120 1123 15115710 10.1136/ard.2003.016451
39. P38 pathway kinases as anti-inflammatory drug targets. JF Schindler JB Monahan WG Smith, J Dent Res 2007 86 9 800 811 17720847
40. Pralnacasan, an inhibitor of interleukin-1β converting enzyme, reduces joint damage in two murine models of osteoarthritis. K Rudolphi N Gerwin N Verzijl P van der Kraan W van der Berg, Osteoarthritis Cartilage 2003 11 738 746 10.1016/S1063-4584(03)00153-5 13129693
41. Chondroprotective effect of intraarticular injections of interleukin-1 receptor antagonist in experimental osteoarthritis. Suppression of collagenase-1 expression. JP Caron JC Fernandes J Martel-Pelletier G Tardif F Mineau C Geng JP Pelletier, Arthritis Rheum 1996 39 1535 1544 10.1002/art.1780390914 8814066
42. p38 MAPK, microglial signaling, and neuropathic pain. RR Ji MR Suter, Molecular Pain 2007 3 33 42 17974036 10.1186/1744-8069-3-33
43. P38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. SX Jin ZY Zhuang CJ Woolf RR Ji, J Neurosci 2003 23 4017 4022 12764087
44. R-13 a novel inhibitor of p38 MAPK, ameliorates hyperalgesia and swelling in arthritis models. Y Wada T Nakajima-Yamada K Yamada J Tsuchida T Yasumoto T Shimozato K Aoki T Kimura S Ushiyama, Eur J Pharmacol 0823 506 285 295 10.1016/j.ejphar.2004.11.013
45. p38 stress-activated protein kinase inhibibtor reverses bradykinin B1 receptor-mediated component of inflammatory hyperalgesia. P Ganju A Davis S Patel X Nunez A Fox, Eur J Pharmacol 2001 421 191 199 10.1016/S0014-2999(01) 01048-2 11516436